BMRN - BioMarin Pharmaceutical Inc.
NEXT EARNINGS:
Apr 29, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$81.54
DETAILS
HIGH:
$100.00
LOW:
$60.00
MEDIAN:
$84.00
CONSENSUS:
$81.54
UPSIDE:
30.21%
Market Cap:
12.03B
Volume:
3,264,412
Avg Volume:
2,720,270
52 Week Range:
50.76-73.51
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.26
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
3,040
IPO Date:
1999-07-26
EPS (TTM):
1.82
P/E Ratio:
32.67
Revenue (TTM):
3.22B
Total Assets:
7.59B
Total Debt:
597.18M
Cash & Equiv:
1.31B
Rev Growth (5Y):
11.6%
EPS Growth (5Y):
-17.5%
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
0.10
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-27 | $0.12 | $-0.15 | +180.0% | $776.1M | $823.5M | -5.7% |
| 2025-08-04 | $1.44 | $0.86 | +67.2% | $825.4M | $761.9M | +8.3% |
| 2025-05-01 | $1.13 | $0.94 | +20.2% | $745.1M | $762.4M | -2.3% |
| 2025-02-19 | $0.92 | $0.54 | +70.4% | $738.2M | $712.3M | +3.6% |
| 2024-10-29 | $0.91 | $0.78 | +16.7% | $745.7M | $712.3M | +4.7% |
| 2024-08-05 | $0.96 | $0.36 | +168.3% | $708.7M | $664.0M | +6.7% |
| 2024-04-24 | $0.71 | $0.31 | +127.7% | $648.8M | $651.8M | -0.5% |
| 2024-02-22 | $0.49 | $0.44 | +11.4% | $646.2M | $636.7M | +1.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.22B | 2.85B | 2.42B | 2.10B | 1.85B | 1.86B | 1.70B | 1.49B | 1.31B | 1.12B | 889.89M | 749.28M |
| Net Income | 348.90M | 426.86M | 167.65M | 141.56M | (64.08M) | 854.03M | (23.85M) | (77.21M) | (117.04M) | (630.21M) | (171.80M) | (133.97M) |
| EPS | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 | 4.75 | -0.13 | -0.44 | -0.67 | -3.80 | -1.07 | -0.92 |
| Total Assets | 7.59B | 6.99B | 6.84B | 6.38B | 6.00B | 5.85B | 4.69B | 4.43B | 4.63B | 4.02B | 3.73B | 2.48B |
| Total Debt | 597.18M | 649.47M | 1.10B | 1.09B | 1.09B | 1.09B | 858.82M | 830.42M | 1.17B | 683.24M | 662.29M | 642.90M |
| Cash & Equivalents | 1.31B | 942.84M | 755.13M | 724.53M | 587.28M | 649.16M | 437.45M | 493.98M | 598.03M | 408.33M | 397.04M | 875.49M |
| Operating Cash Flow | 827.99M | 572.84M | 159.26M | 175.90M | 304.54M | 85.36M | 48.26M | 20.21M | (8.76M) | (227.84M) | (221.69M) | (73.54M) |
| Free Cash Flow | 724.96M | 475.42M | 62.57M | 54.94M | 185.31M | (52.15M) | (96.76M) | (124.41M) | (207.98M) | (376.22M) | (449.34M) | (192.37M) |
| FCF per Share | 3.78 | 2.50 | 0.33 | 0.30 | 1.01 | -0.29 | -0.54 | -0.70 | -1.19 | -2.27 | -2.81 | -1.32 |
| Book Value | 6.09B | 5.66B | 4.95B | 4.60B | 4.27B | 4.11B | 3.12B | 2.97B | 2.81B | 2.77B | 2.40B | 1.53B |
| Cash & ST Investments | 1.56B | 1.14B | 1.07B | 1.29B | 1.01B | 1.07B | 753.81M | 1.08B | 1.40B | 789.68M | 592.62M | 945.19M |
| ROC Equity | 0.06 | 0.08 | 0.03 | 0.03 | -0.02 | 0.21 | -0.01 | -0.03 | -0.04 | -0.23 | -0.07 | -0.09 |